11 results about "Polypyridine complex" patented technology

The invention relates to the technical field of DNA intercalating agents, in particular to a near-infrared luminous ruthenium (II) complex, a preparation method thereof and application of the complex as a DNA intercalating agent. The preparation method comprises the following steps: firstly, preparing a precursor 4 '-(1H-benzimidazole-2-yl)-2, 2': 6 ', 2' '-terpyridyl; then, preparing a target precursor, namely, 2-(4-(anthracene-10-yl)-6-(pyrazine-2-yl) pyridine-2-yl) pyrazine as a ligand; and finally, synthesizing a complex [Ru (An-di (2-Pz) Py) (Bitpy)]. The complex is inserted into a DNA base pair as an intercalating agent, has very strong interaction with DNA, and provides basic research for researching the interaction mode of the ruthenium (II) polypyridine complex of the tridentate ligand and DNA and taking the ruthenium (II) polypyridine complex as a diagnosis and treatment reagent.

The present invention discloses a metal ruthenium complex with a binuclear structure for resisting drug-resistant bacteria, a preparation method and an application thereof, and relates to the field of antibacterial medicine technology. The structure of the complex is as follows:, which can be used to prepare drugs for resisting drug-resistant bacteria, reducing hemolysis of red blood cells, inhibiting MRSA and / or inhibiting the formation of MRSA biofilms. Since the complex contains metal ions and carries four positive charges, compared with traditional organic small molecules, it enhances its ability to penetrate bacterial cell membranes and retention effect, and the multi-coordinate configuration of the metal complex allows it to be modified with different ligands, thereby making it more biologically active. Experiments have shown that the bis-ruthenium polypyridine complex of the present invention can effectively reduce the hemolytic effect of toxins released by MRSA on red blood cells, and can inhibit the formation of MRSA biofilms.

The invention discloses an anti-drug-resistant bacterium metal ruthenium complex with a dual-core structure as well as a preparation method and application thereof, and relates to the technical field of antibacterial medicines. The structure of the complex is as follows: # imgabs0 #, and the complex can be used for preparing drugs for resisting drug-resistant bacteria, relieving red blood cell hemolysis, inhibiting MRSA and / or inhibiting MRSA biofilm formation. The complex contains metal ions and has four positive charges, compared with traditional small organic molecules, the ability of penetrating through bacterial cell membranes and the retention effect of the complex are enhanced, and due to the multi-coordination configuration of the metal complex, the metal complex can be modified by different ligands, so that the biological activity of the metal complex is higher. Experiments prove that the diruthenium polypyridine complex disclosed by the invention can effectively reduce the hemolysis effect of toxin released by MRSA on red blood cells, and can inhibit the formation of an MRSA biological membrane.

The invention discloses a ruthenium polypyridine complex with a sulfonyl fluoride skeleton structure as well as a preparation method and application of the ruthenium polypyridine complex, and belongs to the technical field of antibacterial medicines. According to the ruthenium polypyridine complex with the sulfonyl fluoride structure, ligands obtained after the ruthenium polypyridine complex is coordinated with bipyridines with different substituent groups all carry positive charges and can be combined with negative ions on the surfaces of bacterial cell membranes to damage the bacterial cell membranes, so that bacterial growth is inhibited, and finally bacteria are killed; the introduction of a sulfonyl fluoride structure, a carbon chain structure, an aromatic ring structure and an aromatic heterocyclic structure effectively enhances the biological activity of the complex and the destructive effect on a cell membrane, and bacteria are not easy to secrete alpha-toxin.

The invention belongs to the technical field of antibacterial medicines, and particularly relates to a cinnamyl aldehyde modified polypyridine ruthenium complex for inhibiting hemolysis as well as a preparation method and application of the cinnamyl aldehyde modified polypyridine ruthenium complex. The cinnamyl aldehyde modified ruthenium polypyridine complex disclosed by the invention has a structure as shown in a formula I; in the formula I, the # imgabs0 # has a structure as shown in a formula I1, a formula I2 or a formula I3; the polypyridine ruthenium complex with the cinnamyl aldehyde structure can effectively reduce the hemolysis effect of toxin released by staphylococcus aureus on red blood cells, and the ruthenium complex does not have the tendency of inducing drug resistance of bacteria and can remarkably improve the sensitivity of staphylococcus aureus to aminoglycoside antibiotics. # imgabs1 #

The present invention relates to the field of metal complexes, and in particular to a ruthenium polypyridine complex, a preparation method thereof, and anti-tumor applications. The absorption wavelength of the ruthenium polypyridine complex can be extended to 750 nm, and singlet oxygen can be generated under illumination conditions. The singlet oxygen quantum yield thereof in acetonitrile solution was measured to be 0.54. Compared with the chemotherapy drug cisplatin, the ruthenium polypyridine complex exhibits stronger cytotoxicity, and its toxicity to tumor cells after illumination is greater than that under dark conditions, and has the potential for photodynamic therapy (PDT). The content of the present invention has good clinical application prospects and can be used to further prepare photodynamic anti-tumor drugs.

The invention relates to the field of metal complexes, in particular to a ruthenium polypyridine complex with multiple phototherapy mechanisms as well as a preparation method and anti-lung cancer application of the ruthenium polypyridine complex. The absorption wavelength of the ruthenium polypyridine complex is prolonged to 700nm, and the ruthenium polypyridine complex has good light and dark stability. The complex not only can efficiently generate singlet oxygen after light activation, but also can effectively destroy NADH / NAD < + > redox balance, and shows PDT and photocatalytic cancer treatment dual activities. The complex has relatively low dark toxicity and extremely strong phototoxicity to non-small cell lung cancer cells A549, and after light activation, cell apoptosis can be induced, so that A549 cell death can be caused. The content of the invention is expected to bring new breakthrough to lung cancer treatment.

This invention belongs to the field of antibacterial pharmaceutical technology, and discloses a pyrrole-modified iridium polypyridine complex for antibacterial purposes, its preparation method, and its applications. In the compound structure of the pyrrole-modified iridium polypyridine complex, pyrrole is a penta-nitrogen heterocycle with significant research value. Combined with the metallic element iridium, compared to traditional small organic molecules, it enhances its ability to penetrate bacterial cell membranes, improves transmembrane activity, and effectively penetrates into the bacterial cell membrane, generating ROS-induced oxidative stress, thereby leading to bacterial death. Experiments have demonstrated that the complex of this invention can produce ROS-induced oxidative stress and inhibit biofilm formation.

The invention belongs to the technical field of antibacterial medicines, and particularly relates to a benzenesulfonyl indole structure modified ruthenium polypyridine complex capable of inhibiting bacterial toxins as well as a preparation method and application of the benzenesulfonyl indole structure modified ruthenium polypyridine complex. The ruthenium polypyridine complex with the benzenesulfonyl indole structure, disclosed by the invention, has the following structure: # imgabs0 #; the ruthenium polypyridine complex with the benzenesulfonyl indole structure, disclosed by the invention, not only shows excellent antibacterial ability, but also does not show drug resistance for inducing bacteria. The ruthenium polypyridine complex with the benzenesulfonyl indole structure, disclosed by the invention, can be combined with polymyxin B to play a better antibacterial effect. In addition, research finds that the ruthenium polypyridine complex with the benzenesulfonyl indole structure has a certain anti-biofilm effect, and the action mechanism of the ruthenium polypyridine complex is further researched. The complex can also effectively inhibit the hemolysis phenomenon caused by bacteria, and shows concentration dependence.

The invention discloses a berberine-modified ruthenium polypyridine complex as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The berberine-modified ruthenium polypyridine complex disclosed by the invention has a structure as shown in a formula (I); researches find that the polypyridine ruthenium complex can effectively inhibit the growth of staphylococcus aureus, listeria monocytogenes or micrococcus luteus, has relatively low blood cell toxicity, inhibits the formation of bacterial biofilms, and can effectively reduce the drug resistance problem caused by staphylococcus aureus, listeria monocytogenes or micrococcus luteus; and certain safety is achieved.

The invention discloses a ruthenium polypyridine complex with a multi-ring and quaternary ammonium salt structure as well as a preparation method and application of the ruthenium polypyridine complex. The ruthenium polypyridine complex with the multi-element ring and quaternary ammonium salt structure contains metal ions, has positive charges after being coordinated with dipyridyl with different substituent groups, and can be combined with negative ions on the surface of a bacterial cell membrane to destroy the bacterial cell membrane, so that bacterial growth is inhibited, and bacteria are finally killed. The staphylococcus aureus can generate a multi-layer biological membrane embedded into a cell envelope layer and a mucus layer, and expresses protein with heterogeneity in the whole process, so that permeation of drugs is hindered, the opportunity of host immune escape is increased, bacteria are helped to resist the environment and cause persistent infection, and inhibition of the formation of the biological membrane is the key point of antibacterial medicine technology research. According to the invention, a carbon chain structure, a multi-heterocyclic structure and a quaternary ammonium salt structure are introduced to the ruthenium polypyridine ligand, and the capability of destroying bacterial cell membranes is enhanced through the action of different groups, so that the effect of improving biological activity is achieved.